inebilizumab + IV Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthenia Gravis
Conditions
Myasthenia Gravis
Trial Timeline
Oct 15, 2020 → Nov 29, 2027
NCT ID
NCT04524273About inebilizumab + IV Placebo
inebilizumab + IV Placebo is a phase 3 stage product being developed by Amgen for Myasthenia Gravis. The current trial status is active. This product is registered under clinical trial identifier NCT04524273. Target conditions include Myasthenia Gravis.
What happened to similar drugs?
5 of 20 similar drugs in Myasthenia Gravis were approved
Approved (5) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04524273 | Phase 3 | Active |
Competing Products
20 competing products in Myasthenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 32 |
| tacrolimus | Astellas Pharma | Phase 3 | 40 |
| Tacrolimus capsule + Placebo | Astellas Pharma | Phase 3 | 40 |
| tacrolimus + placebo | Astellas Pharma | Phase 3 | 40 |
| Ravulizumab | AstraZeneca | Pre-clinical | 33 |
| Cladribine Low Dose + Cladribine High Dose | Merck | Phase 3 | 47 |
| Remibrutinib (Blinded) + Remibrutinib (Open Label) | Novartis | Phase 3 | 47 |
| Placebo + CFZ533 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Phase 3 | 47 |
| mycophenolate mofetil [CellCept] + Placebo | Roche | Phase 3 | 40 |
| mycophenolate mofetil (CellCept) + placebo | Roche | Phase 3 | 40 |
| Inebilizumab | Amgen | Phase 2 | 42 |
| Abatacept Injection | Bristol Myers Squibb | Phase 1 | 21 |
| Tolebrutininb + Placebo | Sanofi | Phase 3 | 32 |
| Pozelimab + Cemdisiran + Cemdisiran + Pozelimab | Regeneron Pharmaceuticals | Phase 3 | 44 |
| HIZENTRA ® | CSL | Phase 2 | 35 |
| Subcutaneous immunoglobulins | CSL | Phase 1 | 21 |
| Human normal immunoglobulin G (IgG) | CSL | Phase 3 | 40 |
| zilucoplan (RA101495) | UCB | Phase 3 | 44 |
| zilucoplan (RA101495) + Placebo | UCB | Phase 2 | 35 |